Cargando…

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

OBJECTIVE: To use the large dataset from the Tysabri Outreach: Unified Commitment to Health (TOUCH) program to compare progressive multifocal leukoencephalopathy (PML) risk with natalizumab extended interval dosing (EID) vs standard interval dosing (SID) in patients with multiple sclerosis (MS). MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ryerson, Lana Zhovtis, Foley, John, Chang, Ih, Kister, Ilya, Cutter, Gary, Metzger, Ryan R., Goldberg, Judith D., Li, Xiaochun, Riddle, Evan, Smirnakis, Karen, Kasliwal, Rachna, Ren, Zheng, Hotermans, Christophe, Ho, Pei-Ran, Campbell, Nolan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7010325/ https://www.ncbi.nlm.nih.gov/pubmed/31515290 http://dx.doi.org/10.1212/WNL.0000000000008243

Ejemplares similares

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

Incomplete Susac syndrome exacerbated after natalizumab
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2015)

Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
por: Bsteh, Gabriel, et al.
Publicado: (2017)

Treatment of natalizumab‐associated PML with filgrastim
por: Stefoski, Dusan, et al.
Publicado: (2019)

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
por: Antoniol, Caroline, et al.
Publicado: (2015)

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
por: Dong-Si, Tuan, et al.
Publicado: (2014)

Improving risk‐stratification of natalizumab‐associated PML
por: Tugemann, Bastian, et al.
Publicado: (2021)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome
por: Maillart, Elisabeth, et al.
Publicado: (2017)

Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies
por: Smith, Tyler E, et al.
Publicado: (2022)

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab
por: Toboso, Inmaculada, et al.
Publicado: (2020)

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
por: Butzkueven, Helmut, et al.
Publicado: (2020)

Concomitant granule cell neuronopathy in patients with natalizumab-associated PML
por: Wijburg, Martijn T., et al.
Publicado: (2016)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment
por: Himedan, Mai, et al.
Publicado: (2017)

A link between long-term natalizumab dosing in MS and PML: Putting the puzzle together
por: Major, Eugene O., et al.
Publicado: (2016)

7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study
por: Sinnecker, Tim, et al.
Publicado: (2015)

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study
por: Santiago-Setien, Pilar, et al.
Publicado: (2023)

Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities
por: Honce, Justin M., et al.
Publicado: (2015)

Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing
por: Chang, Ih, et al.
Publicado: (2020)

Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients
por: Reid, Carl E., et al.
Publicado: (2011)

Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus
por: Werner, Milton H., et al.
Publicado: (2016)

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
por: Malucchi, Simona, et al.
Publicado: (2016)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients
por: Lieberman, Linda A., et al.
Publicado: (2016)

Maraviroc in PML-IRIS: A separate ball game under HIV infection and natalizumab?
por: Steiner, Israel, et al.
Publicado: (2017)

COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center
por: Parrotta, Erica, et al.
Publicado: (2020)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
por: Kappos, Ludwig, et al.
Publicado: (2013)

Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial
por: Elkind, Mitchell S.V., et al.
Publicado: (2020)

Metabolic profiles by (1)H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML)
por: Schneider, Ruth, et al.
Publicado: (2017)

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development
por: Meira, Maria, et al.
Publicado: (2016)

Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML
por: Alleg, Manel, et al.
Publicado: (2020)

Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment
por: Muñoz-Vendrell, Albert, et al.
Publicado: (2023)

CD4 cell response to interval therapy with natalizumab
por: Berkovich, Regina, et al.
Publicado: (2015)

Regulation of NF-κB by PML and PML-RARα
por: Ahmed, Abrar, et al.
Publicado: (2017)

Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM
por: Voloshyna, N, et al.
Publicado: (2015)

Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS): “a case report from Ireland with review of literature, clinical pitfalls and future direction”
por: Mansoor, Salman, et al.
Publicado: (2021)

End of dose interval (EDI) symptoms in patients undergoing treatment with natalizumab
por: Magro, Giuseppe, et al.
Publicado: (2021)

Item response theory-based measure of global disability in multiple sclerosis derived from the Performance Scales and related items
por: Chamot, Eric, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_647uott3hnl15d0vkha4spq4j5